Printer Friendly

Cavion Shows T-Type Calcium Channel Modulator CX-8998 as Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model.

M2 PHARMA-November 6, 2018-Cavion Shows T-Type Calcium Channel Modulator CX-8998 as Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model


- US-based biotechnology company Cavion, Inc's first-in-class T-type calcium channel modulator CX-8998 significantly suppressed seizures in two translational animal models of absence epilepsy, the company said.

CX-8998 was more effective than the commonly prescribed anti-epileptic drug ethosuximide in reducing absence seizures in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a highly predictive model of absence epilepsy.

In the GAERS rats, CX-8998 showed near complete suppression of seizure activity (99% reduction in both number and cumulative duration of spike wave discharges) at 10 mg/kg, a well-tolerated dose that results in human-achievable drug concentrations.

In contrast, ethosuximide suppressed 60% of seizure activity at exposures associated with the optimal human dose.

The poster being presented TODAY in the Anticonvulsant and Antiepileptic Therapies Session (289.21) of the Society for Neuroscience annual meeting held in San Diego, CA, also described CX-8998's preclinical efficacy against seizure as tested previously in the WAG/Rij rat model.

T-WAVE ( NCT03406702) is an open-label 15-patient Phase 2a epilepsy clinical trial assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of CX-8998 in adolescents and adults with generalized epileptic syndromes with absence seizures.

Efficacy and pharmacodynamics will be evaluated using digital diaries and quantitative ambulatory EEG readings.

Generalized epilepsies constitute nearly one third of all epilepsies.

While some generalized epileptic syndrome patients with absence seizures respond to first line antiepileptic drugs and have a generally good prognosis, a significant proportion fail to achieve adequate control with existing therapeutics or experience intolerable side effects.

For these patients, the goal is to achieve seizure control while limiting side effects and negative impacts, especially on cognitive outcomes.

Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.

The company portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures.

Cavion recently announced promising results of their T-CALM proof-of-concept study assessing CX-8998 for essential tremor.

SynapCell is an innovative, brain-focused biotechnology company that provides pharmaceutical companies with a set of predictive solutions designed to evaluate drug candidates' efficacy on central nervous system disorders.

Having first developed its solutions for epilepsy, the company expanded its offerings in 2015 to address motor (Parkinson's disease) and cognitive (Alzheimer's disease, autism and schizophrenia) disorders, providing its international clients with Go/No-Go decision capability to progress the discovery of new treatments for CNS disorders.

((Comments on this story may be sent to
COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 6, 2018
Previous Article:BlackThorn Therapeutics Names Martin as President and Chief Operating Officer.
Next Article:Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters